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Abstract
Background: Although rubella is generally considered a benign childhood disease, infection of a pregnant woman
can cause foetal congenital rubella syndrome, which results in embryo-foetal disease and malformations. The
syndrome is still a public health problem in developing countries where the vaccine has not yet been introduced, such
as the Central African Republic (CAR). The aim of the study reported here was to define the epidemiology of primary
rubella infection, in order to determine its effect on morbidity rates in the country.
Methods: Data derived from epidemiological surveillance of measles and rubella were analysed retrospectively
between 1 January 2007 and 31 December 2014. The database includes cases of suspected measles, according to the
WHO clinical case definition. In this algorithm, samples that are negative or doubtful by ELISA for measles (presence
of immunoglobulin M) are tested in another ELISA for detection of rubella-specific IgM. Descriptive analyses were
conducted for socio-demographic characteristics, including age, sex and health region, for patients tested for rubella.
Results: Of the sera tested for rubella, 30.2 % (425/1409) were positive, 62.3 % (878/1409) were negative, and 7.5 %
(106/1409) were doubtful. Among the 425 positive cases, 213 (50.1 %) were female and 212 (40.9 %) were male with
a sex ratio of 1.03. The mean age was 8 years (range, 6–37 years). The highest prevalence (47.3 %; 116/425) was seen
in 2007 and the lowest (8.9 %; 11/425) in 2012. Primary infections were always more frequent during the
first 3 months of the year, with a peak at the same time, between January and February which is the hottest
period of the year in the CAR. In both sexes, rubella IgM was rarely found before the age of 1 year (0.5 %;
2/425). The highest rate (43.5 %; 185/425) was observed at ages 5–9 years; however, at least 8 % (18/213) of
girls aged 15 or more had primary infections.
Conclusions: Sentinel sites for surveillance of congenital rubella syndrome are urgently needed, and
introduction of vaccination against rubella in the Expanded Programme of Immunization should be
considered, to ensure immunization of girls of reproductive age.
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Background
Rubella is an infectious disease caused by an RNA enve-
lope virus of the Togaviridae family and the Rubivirus
genus. This strictly human virus, which is transmitted in
aerosols, usually causes a benign infection in children
and young adults. Its public health importance is due to
the mother’s risk for congenital rubella syndrome after a
primary infection at the beginning of pregnancy. The
syndrome is associated with embryo and foetal disease
and congenital malformations [1, 2].
The prevalence of primary infection is difficult to de-
termine, but there are an estimated 110 000 cases of
congenital rubella syndrome each year in developing
countries, even though this is a vaccine-preventable dis-
ease and rubella is a viral disease that could potentially
be eradicated [3, 4].
The prevalence of infections by specific rubella IgM
detection reported by the World Health Organisation
(WHO) for the Africa region between 2002 and 2009
ranged from 13 and 38 % [1]. Evaluations of the surveil-
lance of rubella infection in Ethiopia between 2004 and
2009 and in Nigeria in 2011 have respectively reported a
prevalence of 12.1 and 45.2 % [5, 6]. In Central African
Republic (CAR), a study on the seroprevalence of natural
measles and rubella antibodies in children under 15 year,
based on the detection of IgG in Bangui had reported in
2008 an overall prevalence of 55.4 % for rubella [7]. But
no studies had yet dealt with the assessment of the
primo infection based on the detection of specific IgM.
The expanded programme of immunization estab-
lished in CAR by the Ministry of Health in 1979 with
the support of the World Health Organization
(WHO) and UNICEF still does not include rubella
vaccine. Measles vaccine is administered at the age of
9 months, with an estimated coverage of 50 % in
2014 and 33 % in the first 3 months of 2015; these
rates are too low for WHO to consider introducing
rubella vaccine in the CAR [2]. Although the Institut
Pasteur de Bangui commercializes the trivalent vac-
cine against measles, mumps and rubella, few children
have access to it because of its high cost: in 2007–
2014, only 369 children were vaccinated, correspond-
ing to about 50 per year. Therefore, children are
generally immunized naturally, by primary infection;
when a pregnant woman is infected, is at risk for
congenital rubella syndrome [8].
Epidemiological surveillance of measles and rubella
has been conducted in the CAR since 2007. The samples
that are negative for measles are systematically tested for
primary rubella infection by differential diagnosis ac-
cording to the WHO-recommended algorithm [1, 9].
The enteric viruses and measles laboratory at the Institut
Pasteur de Bangui is a WHO national reference labora-
tory for measles and is the only structure for sero-
surveillance in the country. In this study, we evaluated
the epidemiology of primary rubella infection between
2007 and 2014 in the CAR.
Methods
Study site and demographic data
The CAR, in the heart of the African continent, covers
an area of 623 000 km2 and has an equatorial climate,
with two seasons: a rainy season between May and
October and a dry season between November and April.
The population, which was 3 895 139 in 2003, is esti-
mated on the basis of a natural annual growth of 2.5 %
to be 4 200 854 in 2007 and 4 854 905 in 2014. The
regional distribution of this mainly rural population
(61 %) results in a density of 11 people per km2 in the
west and < 1/km2 in the east; in the centre, the south
and the south-east, the density varies from 7.2/km2 to
10 041.38/km2 in the capital, Bangui [10]. The health
system is decentralized into seven regions to ensure
effective coverage with health programmes.
Database, target population and sampling
Data from sero-surveillance of measles and rubella be-
tween 1 January 2007 and 31 December 2014 were ana-
lysed retrospectively. The Epi Info database includes
information on the type of sample, its origin and socio-
demographic data on the donors.
Patients who gave samples met the WHO standard
definition of suspected cases of measles, i.e. generalized
maculopapular rash and fever, with at least one of the
following symptoms: cough, rhinitis or conjunctivitis;
the samples were taken within 28 days of the beginning
of the rash [1]. The samples consisted of 1–5 ml of
venous blood drawn into dry tubes and transported in
refrigerated sample carriers at 4 °C - 8 °C to the labora-
tory within 3 days of sampling. Urine samples and throat
swabs, which might have assisted diagnosis, were not
used.
Samples were taken in all seven health regions, and
transport to the laboratory was ensured both by trained
focal points in the health regions and by nongovernmen-
tal organizations such as Médecins sans Frontières and
Médecins du Monde.
The data obtained for each patient were: age, sex,
history of vaccination against measles, date of onset of
clinical signs, dates of sampling and hospitalization.
Laboratory analyses
First, the measles IgM research was performed on all
samples. According to the algorithm defined by WHO,
samples negative or doubtful for measles were tested for
rubella in an indirect enzyme-linked immunosorbent
assay (ELISA) for quantitative detection of specific
rubella virus immunglobulin (Ig) M (Anti-rubella Virus/
Farra et al. BMC Infectious Diseases  (2016) 16:505 Page 2 of 6
IgM Enygnost, Siemens). This test has a sensitivity of
98 % and a specificity of 97.3 %. The sensitivity and the
specificity of the test have been made optimum by the
initial treatment of Sera by the absorbing factor from the
Kit, that forming an immuno-complex with the IgG to
neutralize the rheumatoid factors in Sera. In accordance
with the criteria of validity for the test, sera with an
optical density < 0.10 were considered negative, 0.10–
0.20 as doubtful and > 0.2 as positive. The results were
entered into the Epi Info measles database.
Data analysis
The data collected were treated and analysed with Epi
Info version 7 software and Excel. Descriptive analyses
were conducted for the sociodemographic characteristics
age, sex and health region.
Results
Characteristics of the study population
One thousand four hundred nine persons were in-
volved in this study. The average age of the test sub-
jects was 8 years with extremes ranging from
6 months to 37 years, the male/female sex ratio was
1.03. The numbers of subjects living in urban areas
was 1002/1409 (71.1 %) against 407/1409 (28.9 %) in
rural areas.
Prevalence
Between January 2007 and December 2014, 1409 sera
were tested for rubella-specific IgM; 30.2 % were posi-
tive, 62.3 % negative and 7.5 % doubtful (Table 1). The
highest prevalence was seen in 2007 (47.3 %), followed
by 2014 (37.7 %) and 2009 (30.8 %). The lowest preva-
lence was seen in 2012 (8.9 %).
Distribution of seroprevalence by health region
Figure 1 shows that laboratory-confirmed rubella was
present in all seven regions, with the highest preva-
lence in health region 7 (237/630, 37.6 %), followed
by region 1 (54/156, 34.6 %), and the lowest in region
3 (18/113, 16.0 %).
Distribution of seroprevalence by month, 2007–2014
Although cases are notified throughout the year, they
occur mainly during the first 3 months, with a peak in
January and February. In 2014, however, the notification
rate remained higher throughout the year, with a second
peak between July and August (Fig. 2). This peak
affected particularly the region 7 where the number of
positive IgM was 144 /184 (78.3 %).
Distribution of seroprevalence by age and sex
Table 2 shows that rubella-specific IgM was present in
equal proportions of girls (50.1 %) and boys (49.9 %).
Rubella was rarely found before the age of 1 year (0.5 %)
in either sex. Immunization begins from the age of 1 year,
with a peak between 5 and 9 years (43.5 %). After the
age of 15 years, at least 8 % of girls still had primary
infections.
Discussion
Between 2007 and 2014, 425 laboratory-confirmed cases
of rubella were found in 1409 samples from the seven
health regions of the CAR, for a prevalence of 30.2 %;
62.3 % were negative and 7.5 % doubtful. These results
are similar to those from laboratory surveillance in 40
countries in the WHO African Region, which showed a
prevalence of 24.3 % (25 631/105 250), with 66 % nega-
tive and 4 % doubtful [1]. Although these data appear to
be similar across countries, it is not clear whether they
really define the epidemiological profile of rubella in
Africa, as all the patients included had suspected mea-
sles [5]. The more than 60 % negative results obtained in
this study and that of WHO for all countries might be
due to the inclusion of children with other eruptive
febrile illnesses of unknown aetiology, such as chicken
pox, roseola, scarlet fever and iatrogenic skin rashes.
Furthermore, samples taken very early, within 3 days of
Table 1 Results by year for suspected measles cases and rubella serology, 2007–2014
Year Suspected
measles case
No. of sera tested
in rubella
Rubella IgM
Positive Negative Doubtful
2007 256 245 (95.7 %) 116 (47.3 %) 111 (45.3 %) 18 (7.4 %)
2008 116 104 (89.6 %) 22 (21.2 %) 77 (74 %) 5 (4.8 %)
2009 119 107 (90 %) 33 (30.8 %) 69 (64.5 %) 5 (4.7 %)
2010 95 93 (97.9 %) 14 (15.1 %) 77 (82.8 %) 2 (2.1 %)
2011 158 84 (53.2 %) 15 (17.8 %) 64 (76.2 %) 5 (6 %)
2012 190 123 (64.7 %) 11 (8.9 %) 103 (83.8 %) 9 (7.3 %)
2013 380 165 (43.4 %) 30 (18.2 %) 115 (69.7 %) 20 (12.1 %)
2014 722 488 (67.6 %) 184 (37.7 %) 262 (53.7 %) 42 (8.6 %)
All 2036 1409 (69.2 %) 425 (30.2 %) 878 (62.3 %) 106 (7.5 %)
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the start of illness, or late, at > 28 days after the start,
might not have had high enough antibody titres to be
detected serologically [5]. Monitoring such that it has
been implemented in the African region of WHO relies
solely on searching of specific IgM in sera from com-
mercial ELISA kits. Since the 1980’s it is well known that
IgM positive test is not enough to assert a primary
rubella infection, because some viral infections like
Epstein Barr virus infection (EBV), cytomegalovirus
(CMV) or human parvovirus B19 (HPV-B19) can cause
a cross-reaction with rubella infection [11–16]. This
shows the limits of these surveillance programs in gen-
eral and particular of this study, especially that IgG avid-
ity tests were not performed to assert the primary
rubella infection [15].
High primary infection rates were always seen during
the first 3 months of each year, with a peak at exactly
the same time, between January and February, which is
the hottest period of the year. The influence of a hot,
dry climate on peaks of infection and high disease preva-
lence were also reported in the USA before vaccination
was introduced [17, 18]. High transmission during this
period is associated with dry mucosa, with micro-lesions
induced by breathing hot, dry air. The finding of the
highest prevalence in health region 7 may be due to the
high population density (10 000/km2), which would
result in high transmission rates [17].
The primo infection was more observed in the urban
population probably because in CAR, population lives
preferentially in urban areas where the density is higher
Fig. 1 Distribution of rubella IgM by health region, 2007–2014
Fig. 2 Distribution of cases of rubella by month, 2001–2014
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than in rural areas characterized by a disparate popula-
tion. In other studies such as the one in Ethiopia, the
population is rural to almost 83 % which may justify that
a strong predominance is found in this environment [5].
Furthermore, during 2014 CAR experienced several
military events that induced population movements all
over the country, especially in region 7. Entire families
found themselves in displaced camps which could
promote the spread within groups and explain this peak
between July and October.
The distribution of primary infection by age showed
virtually no immunization before the age of 1 year
(0.5 %), a rate of 19.5 % between 1 and 4 years, 43.5 %
between 5 and 9 years, 28 % between 10 and 14 years
and 9.6 % in children over 15 years. The data reported
by WHO for the countries of the African Region are
similar, with 3 % at < 1 year, 28 % between 1 and 4 years,
47 % between 5 and 9 years, 16 % between 10 and
14 years and 5 % in children over 15 years [1]. The low
prevalence before 1 year of age may be due to passive
immunization by maternal antibodies; children have pri-
mary infections after that age, with a peak between 5
and 9 years. This age range was associated with high
levels of rubella infection even in developed countries,
such as Australia, European countries and the USA, be-
fore introduction of the vaccine; children of these ages
often spend time in high-density public places, such as
schools, care establishments and leisure centres, which
could contribute to propagation of infection [19].
We found little difference between the sexes, as in
other studies [6, 20, 21]. This implies that, if vaccin-
ation were included in the expanded programme in
the CAR, both sexes should be targeted in order to
reduce circulation of the virus in communities [22].
In the absence of vaccination, 8.4 % of girls at least
15 years of age, who are of reproductive age, could
expose their foetus to congenital rubella syndrome.
The prevalence in the WHO African Region is 5 %,
and a prevalence of 15–20 % has been reported in
some studies [1, 22, 23]. The risk for congenital ru-
bella is real, as demonstrated by the results of this
study and in other African countries; however, lack of
notification of cases, due to the absence of a system
of surveillance, has concealed this fact [1]. Sentinel
sites for the surveillance of congenital rubella syn-
drome should be established to evaluate the true
burden among women of reproductive age in our
countries, where immunization against rubella is still
acquired randomly by primary infection.
Conclusions
This retrospective study allowed us to determine the an-
nual incidence and epidemiology of rubella between
2007 and 2014 in the CAR. Although rubella is a child-
hood disease, a substantial number of girls of reproduct-
ive age are exposed to primary infection and thus may
transmit the virus in utero, with a risk for congenital ru-
bella syndrome. Seasonality appears to be a key factor in
transmission in the CAR and also the size of the popula-
tion in which the disease occurs. We hope that these
results will detrmine the Department of Health of the
CAR and partners to use a better approach to epidemio-
logical surveillance, particularly for congenital rubella
syndrome. In the light of these results, the question of
introducing rubella vaccine into the expanded
programme should be addressed, while at the same time
improving coverage with measles vaccine, in order to
ensure that the children of the country are immunized
against these two viral diseases.
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